A New Investigation: Levi & Korsinsky, LLP Notifies Revance Therapeutics Stockholders
New York, NY, February 25, 2025 – In a recent press release, Levi & Korsinsky, LLP, a prominent securities law firm, announced the initiation of an investigation into the fairness of the acquisition of Revance Therapeutics Inc. (RVNC) by Crown Laboratories, Inc. (Crown).
The Background:
Revance Therapeutics Inc., a biotechnology company based in New Jersey, focuses on developing and commercializing novel drugs for aesthetics and other therapeutic areas. Meanwhile, Crown Laboratories, a specialty pharmaceutical company headquartered in North Carolina, has agreed to acquire Revance in a cash and stock transaction valued at approximately $1.1 billion.
The Investigation:
Levi & Korsinsky, LLP encourages all persons or entities who purchased Revance Therapeutics Inc. stock prior to August 11, 2024, to contact the firm regarding their potential eligibility to recover damages arising from the transaction. The investigation focuses on whether the acquisition consideration is fair, in light of the potential misleading statements or omissions from Revance Therapeutics, Inc. and/or Crown Laboratories, Inc. regarding the merits and fairness of the transaction.
Impact on Individual Stockholders:
If you are a Revance Therapeutics Inc. stockholder who purchased Revance Therapeutics Inc. stock prior to August 11, 2024, and wish to learn more about the investigation or your potential recovery options, please contact Levi & Korsinsky, LLP. The investigation may result in significant financial recovery for affected stockholders.
Impact on the World:
The investigation into the Revance acquisition by Crown Laboratories may have broader implications for the biotech industry and M&A market as a whole. If the investigation uncovers material misstatements or omissions, it could potentially discourage investors’ confidence in similar transactions and lead to increased scrutiny of mergers and acquisitions in the sector.
Conclusion:
As a Revance Therapeutics Inc. stockholder, you have an opportunity to be part of an important investigation into the fairness of the acquisition by Crown Laboratories. Levi & Korsinsky, LLP is dedicated to ensuring that all parties involved in this transaction are held accountable for their actions, and potential damages may be recovered for affected stockholders. For more information, please contact Levi & Korsinsky, LLP at (212) 363-7571 or via email at [email protected].
- Levi & Korsinsky, LLP initiates an investigation into the Revance Therapeutics Inc. acquisition by Crown Laboratories.
- Stockholders who purchased RVNC stock prior to August 11, 2024, may be eligible to recover damages.
- The investigation focuses on potential misstatements or omissions regarding the fairness of the transaction.
- Impact on individual stockholders and the biotech industry as a whole.
